Literature DB >> 21220609

Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications.

Guido Marcucci1, Torsten Haferlach, Hartmut Döhner.   

Abstract

Molecular analyses of leukemic blasts from patients with acute myeloid leukemia (AML) have revealed a striking heterogeneity with regard to the presence of acquired gene mutations and changes in gene and microRNA expression. Multiple submicroscopic genetic alterations with prognostic significance have been discovered. Application of gene- and microRNA profiling has identified genome-wide expression signatures that separate cytogenetic and molecular subsets of patients with AML into previously unrecognized biologic and/or prognostic subgroups. These and similar future findings are likely to have a major impact on the clinical management of AML because many of the identified genetic alterations not only represent independent prognosticators, but also may constitute targets for specific therapeutic intervention. In this report, we review genetic findings in AML and discuss their clinical implications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21220609     DOI: 10.1200/JCO.2010.30.2554

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  197 in total

Review 1.  [Malignancy potential of precursor lesions: determination using molecular markers].

Authors:  A Jung
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

2.  New opportunities and new problems for acute myeloid leukemia treatment.

Authors:  Idoya Lahortiga; Jan Cools
Journal:  Haematologica       Date:  2012-06       Impact factor: 9.941

Review 3.  Molecular therapy for acute myeloid leukaemia.

Authors:  Catherine C Coombs; Martin S Tallman; Ross L Levine
Journal:  Nat Rev Clin Oncol       Date:  2015-12-01       Impact factor: 66.675

Review 4.  New drugs for acute myeloid leukemia inspired by genomics and when to use them.

Authors:  Daniel A Pollyea
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

5.  Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia.

Authors:  Aziz Nazha; Jorge Cortes; Stefan Faderl; Sherry Pierce; Naval Daver; Tapan Kadia; Gautam Borthakur; Raja Luthra; Hagop Kantarjian; Farhad Ravandi
Journal:  Haematologica       Date:  2012-04-24       Impact factor: 9.941

6.  Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.

Authors:  Zejuan Li; Tobias Herold; Chunjiang He; Peter J M Valk; Ping Chen; Vindi Jurinovic; Ulrich Mansmann; Michael D Radmacher; Kati S Maharry; Miao Sun; Xinan Yang; Hao Huang; Xi Jiang; Maria-Cristina Sauerland; Thomas Büchner; Wolfgang Hiddemann; Abdel Elkahloun; Mary Beth Neilly; Yanming Zhang; Richard A Larson; Michelle M Le Beau; Michael A Caligiuri; Konstanze Döhner; Lars Bullinger; Paul P Liu; Ruud Delwel; Guido Marcucci; Bob Lowenberg; Clara D Bloomfield; Janet D Rowley; Stefan K Bohlander; Jianjun Chen
Journal:  J Clin Oncol       Date:  2013-02-04       Impact factor: 44.544

7.  Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells.

Authors:  Shanshan Pei; Mohammad Minhajuddin; Angelo D'Alessandro; Travis Nemkov; Brett M Stevens; Biniam Adane; Nabilah Khan; Fred K Hagen; Vinod K Yadav; Subhajyoti De; John M Ashton; Kirk C Hansen; Jonathan A Gutman; Daniel A Pollyea; Peter A Crooks; Clayton Smith; Craig T Jordan
Journal:  J Biol Chem       Date:  2016-08-29       Impact factor: 5.157

8.  Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis.

Authors:  Jian-Hua Feng; Xiao-Ping Guo; Yuan-Yuan Chen; Zhu-Jun Wang; Yu-Ping Cheng; Yong-Min Tang
Journal:  Am J Blood Res       Date:  2012-11-25

9.  HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy.

Authors:  Glenda J Dickson; Fabio G Liberante; Laura M Kettyle; Kathleen A O'Hagan; Damian P J Finnegan; Lars Bullinger; Dirk Geerts; Mary Frances McMullin; Terry R J Lappin; Ken I Mills; Alexander Thompson
Journal:  Haematologica       Date:  2013-03-28       Impact factor: 9.941

10.  Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.

Authors:  Daniel A Pollyea; James Zehnder; Steve Coutre; Jason R Gotlib; Leonel Gallegos; Omar Abdel-Wahab; Peter Greenberg; Bing Zhang; Michaela Liedtke; Caroline Berube; Ross Levine; Beverly S Mitchell; Bruno C Medeiros
Journal:  Haematologica       Date:  2012-12-14       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.